Pros and cons of VP1-specific maternal IgG for the protection of Enterovirus 71 infection

Vaccine

Volumn 33, Issue 48, 2015, Pages 6604-6610

  Kim, Young In ^a   Song, Jae Hyoung ^b   Kwon, Bo Eun ^b   Kim, Ha Neul ^a   Seo, Min Duk ^a   Park, KwiSung ^c   Lee, SangWon ^d   Yeo, Sang Gu ^d   Kweon, Mi Na ^e   Ko, Hyun Jeong ^b   Chang, Sun Young ^a  

^a Ajou University   (South Korea)

^b Kangwon National University   (South Korea)

^c Chungcheongnam Do Institute of Health and Environment Research   (South Korea)

^d Korea National Institute of Health   (South Korea)

^e University of Ulsan College of Medicine   (South Korea)

Author keywords

Enterovirus 71; Maternal IgG; Pre existing immunity; Protective immunity; VP1

Indexed keywords

IMMUNOGLOBULIN G; MATERNAL ANTIBODY; PROTEIN VP1; RECOMBINANT PROTEIN; RECOMBINANT VIRAL CAPSID PROTEIN 1; UNCLASSIFIED DRUG; VIRAL PROTEIN; VIRUS ANTIBODY; VIRUS VACCINE;

ACTIVE IMMUNIZATION; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIBODY PRODUCTION; ARTICLE; CONTROLLED STUDY; ENTEROVIRUS 71; ENTEROVIRUS INFECTION; FEMALE; HOST CELL; INFECTION PREVENTION; MALE; MEMORY CELL; MESENTERY LYMPH NODE; MONONUCLEAR CELL; MOUSE; NEWBORN; NEWBORN INFECTION; NONHUMAN; PREGNANCY; PRIORITY JOURNAL; PROGENY; SECRETORY CELL; VIRUS CAPSID; VIRUS IMMUNITY; VIRUS NEUTRALIZATION; VIRUS STRAIN; ANIMAL; BAGG ALBINO MOUSE; BLOOD; CHEMISTRY; DISEASE MODEL; ENTEROVIRUS A; ENTEROVIRUS INFECTIONS; GENETICS; HUMORAL IMMUNITY; IMMUNOLOGY; PASSIVE IMMUNIZATION;

ANIMALS; ANTIBODIES, VIRAL; DISEASE MODELS, ANIMAL; ENTEROVIRUS A, HUMAN; ENTEROVIRUS INFECTIONS; FEMALE; IMMUNITY, HUMORAL; IMMUNITY, MATERNALLY-ACQUIRED; IMMUNOGLOBULIN G; MICE; MICE, INBRED BALB C; VIRAL STRUCTURAL PROTEINS; VIRAL VACCINES;

EID: 84949773096     PISSN: 0264410X     EISSN: 18732518     Source Type: Journal    
DOI: 10.1016/j.vaccine.2015.10.103     Document Type: Article

References (31)

1. Song J.H., Choi H.J., Song H.H., Hong E.H., Lee B.R., Oh S.R., et al. Antiviral activity of ginsenosides against coxsackievirus B3, enterovirus 71, and human rhinovirus 3. J Ginseng Res 2014, 38:173-179.
2. Song J., Yeo S.G., Hong E.H., Lee B.R., Kim J.W., Kim J., et al. Antiviral activity of hederasaponin B from Hedera helix against Enterovirus 71 subgenotypes C3 and C4a. Biomol Ther (Seoul) 2014, 22:41-46.
3. Zhou S.L., Ying X.L., Han X., Sun X.X., Jin Q., Yang F. Characterization of the enterovirus 71 VP1 protein as a vaccine candidate. J Med Virol. 2015, 87:256-262.
4. Chang L.Y., Hsiung C.A., Lu C.Y., Lin T.Y., Huang F.Y., Lai Y.H., et al. Status of cellular rather than humoral immunity is correlated with clinical outcome of enterovirus 71. Pediatr Res 2006, 60:466-471.
5. Wu C.N., Lin Y.C., Fann C., Liao N.S., Shih S.R., Ho M.S. Protection against lethal enterovirus 71 infection in newborn mice by passive immunization with subunit VP1 vaccines and inactivated virus. Vaccine 2001, 20:895-904.
6. Wang M., Jiang S., Wang Y. Recombinant VP1 protein expressed in Pichia pastoris induces protective immune responses against EV71 in mice. Biochem Biophys Res Commun 2013, 430:387-393.
7. Li H.Y., Han J.F., Qin C.F., Chen R. Virus-like particles for enterovirus 71 produced from Saccharomyces cerevisiae potently elicits protective immune responses in mice. Vaccine 2013, 31:3281-3287.
8. Mao Q., Dong C., Li X., Gao Q., Guo Z., Yao X., et al. Comparative analysis of the immunogenicity and protective effects of inactivated EV71 vaccines in mice. PLoS ONE 2012, 7:e46043.
9. Li R., Liu L., Mo Z., Wang X., Xia J., Liang Z., et al. An inactivated enterovirus 71 vaccine in healthy children. N Engl J Med 2014, 370:829-837.
10. Zhu F., Xu W., Xia J., Liang Z., Liu Y., Zhang X., et al. Efficacy, safety, and immunogenicity of an enterovirus 71 vaccine in China. N Engl J Med 2014, 370:818-828.
11. Chen H.L., Huang J.Y., Chu T.W., Tsai T.C., Hung C.M., Lin C.C., et al. Expression of VP1 protein in the milk of transgenic mice: a potential oral vaccine protects against enterovirus 71 infection. Vaccine 2008, 26:2882-2889.
12. Czerkinsky C.C., Nilsson L.A., Nygren H., Ouchterlony O., Tarkowski A. A solid-phase enzyme-linked immunospot (ELISPOT) assay for enumeration of specific antibody-secreting cells. J Immunol Methods 1983, 65:109-121.
13. Yamayoshi S., Koike S. Identification of a human SCARB2 region that is important for enterovirus 71 binding and infection. J Virol 2011, 85:4937-4946.
14. Arita M., Nagata N., Iwata N., Ami Y., Suzaki Y., Mizuta K., et al. An attenuated strain of enterovirus 71 belonging to genotype a showed a broad spectrum of antigenicity with attenuated neurovirulence in cynomolgus monkeys. J Virol 2007, 81:9386-9395.
15. Roldao A., Mellado M.C., Castilho L.R., Carrondo M.J., Alves P.M. Virus-like particles in vaccine development. Expert Rev Vaccines 2010, 9:1149-1176.
16. Ku Z., Liu Q., Ye X., Cai Y., Wang X., Shi J., et al. A virus-like particle based bivalent vaccine confers dual protection against enterovirus 71 and coxsackievirus A16 infections in mice. Vaccine 2014, 32:4296-4303.
17. Tung W.S., Bakar S.A., Sekawi Z., Rosli R. DNA vaccine constructs against enterovirus 71 elicit immune response in mice. Genet Vaccines Ther 2007, 5:6.
18. Foo D.G., Alonso S., Chow V.T., Poh C.L. Passive protection against lethal enterovirus 71 infection in newborn mice by neutralizing antibodies elicited by a synthetic peptide. Microbes Infect 2007, 9:1299-1306.
19. Hu Y.M., Wang X., Wang J.Z., Wang L., Zhang Y.J., Chang L., et al. Immunogenicity, safety, and lot consistency of a novel inactivated enterovirus 71 vaccine in Chinese children aged 6 to 59 months. Clin Vaccine Immunol 2013, 20:1805-1811.
20. Simister N.E. Placental transport of immunoglobulin G. Vaccine 2003, 21:3365-3369.
21. Roopenian D.C., Akilesh S. FcRn: the neonatal Fc receptor comes of age. Nat Rev Immunol 2007, 7:715-725.
22. Bek E.J., Hussain K.M., Phuektes P., Kok C.C., Gao Q., Cai F., et al. Formalin-inactivated vaccine provokes cross-protective immunity in a mouse model of human enterovirus 71 infection. Vaccine 2011, 29:4829-4838.
23. Ong K.C., Devi S., Cardosa M.J., Wong K.T. Formaldehyde-inactivated whole-virus vaccine protects a murine model of enterovirus 71 encephalomyelitis against disease. J Virol 2010, 84:661-665.
24. Kitikoon P., Nilubol D., Erickson B.J., Janke B.H., Hoover T.C., Sornsen S.A., et al. The immune response and maternal antibody interference to a heterologous H1N1 swine influenza virus infection following vaccination. Vet Immunol Immunopathol 2006, 112:117-128.
25. Niewiesk S. Maternal antibodies: clinical significance, mechanism of interference with immune responses, and possible vaccination strategies. Front Immunol 2014, 5:446.
26. Getahun A., Heyman B. Studies on the mechanism by which antigen-specific IgG suppresses primary antibody responses: evidence for epitope masking and decreased localization of antigen in the spleen. Scand J Immunol 2009, 70:277-287.
27. Karlsson M.C., Getahun A., Heyman B. FcgammaRIIB in IgG-mediated suppression of antibody responses: different impact in vivo and in vitro. J Immunol 2001, 167:5558-5564.
28. Saxena M., Van T.T., Baird F.J., Coloe P.J., Smooker P.M. Pre-existing immunity against vaccine vectors-friend or foe. Microbiology 2013, 159:1-11.
29. Madhi S.A., Cunliffe N.A., Steele D., Witte D., Kirsten M., Louw C., et al. Effect of human rotavirus vaccine on severe diarrhea in African infants. N Engl J Med 2010, 362:289-298.
30. Jiang V., Jiang B., Tate J., Parashar U.D., Patel M.M. Performance of rotavirus vaccines in developed and developing countries. Hum Vaccin 2010, 6:532-542.
31. Fujii K., Nagata N., Sato Y., Ong K.C., Wong K.T., Yamayoshi S., et al. Transgenic mouse model for the study of enterovirus 71 neuropathogenesis. Proc Natl Acad Sci USA 2013, 110:14753-14758.